141 related articles for article (PubMed ID: 18164268)
21. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes.
Xue G; Restuccia DF; Lan Q; Hynx D; Dirnhofer S; Hess D; Rüegg C; Hemmings BA
Cancer Discov; 2012 Mar; 2(3):248-59. PubMed ID: 22585995
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
23. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
24. [Effect of Evn-50 on cell growth and apoptosis in tamoxifen-resistance human breast cancer cell line MCF-7/TAM-R].
Hu HY; Zhou J; Wan F; Dong LF; Zhang F; Wang YK; Chen FF; Chen YD
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):498-505. PubMed ID: 23086641
[TBL] [Abstract][Full Text] [Related]
25. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
[TBL] [Abstract][Full Text] [Related]
26. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
Ojo D; Wu Y; Bane A; Tang D
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
28. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
[TBL] [Abstract][Full Text] [Related]
29. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells.
Perry RR; Kang Y; Greaves BR
Br J Cancer; 1995 Dec; 72(6):1441-6. PubMed ID: 8519657
[TBL] [Abstract][Full Text] [Related]
30. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells.
Choi HK; Yang JW; Roh SH; Han CY; Kang KW
Endocr Relat Cancer; 2007 Jun; 14(2):293-303. PubMed ID: 17639045
[TBL] [Abstract][Full Text] [Related]
31. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.
Duan L; Calhoun S; Shim D; Perez RE; Blatter LA; Maki CG
J Mol Cell Biol; 2021 Sep; 13(6):433-444. PubMed ID: 33755174
[TBL] [Abstract][Full Text] [Related]
33. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity.
Shekhar MP; Santner S; Carolin KA; Tait L
Am J Pathol; 2007 May; 170(5):1546-60. PubMed ID: 17456761
[TBL] [Abstract][Full Text] [Related]
34. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
35. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen-induced cytotoxicity in breast cancer cells is mediated by glucose-regulated protein 78 (GRP78) via AKT (Thr308) regulation.
Pujari R; Jose J; Bhavnani V; Kumar N; Shastry P; Pal JK
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):57-67. PubMed ID: 27262235
[TBL] [Abstract][Full Text] [Related]
37. TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.
Zu X; Zhong J; Tan J; Tan L; Yang D; Zhang Q; Ding W; Liu W; Wen G; Liu J; Cao R; Jiang Y
Int J Mol Med; 2015 Mar; 35(3):693-701. PubMed ID: 25572132
[TBL] [Abstract][Full Text] [Related]
38. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
[TBL] [Abstract][Full Text] [Related]
39. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.
deGraffenried LA; Chandrasekar B; Friedrichs WE; Donzis E; Silva J; Hidalgo M; Freeman JW; Weiss GR
Ann Oncol; 2004 Jun; 15(6):885-90. PubMed ID: 15151944
[TBL] [Abstract][Full Text] [Related]
40. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]